127 related articles for article (PubMed ID: 19605761)
21. Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy.
Wang R; Zhang Y; Shan F
Int Immunopharmacol; 2019 Oct; 75():105785. PubMed ID: 31404891
[TBL] [Abstract][Full Text] [Related]
22. The opioid growth factor, [Met5]-enkephalin, and the zeta opioid receptor are present in human and mouse skin and tonically act to inhibit DNA synthesis in the epidermis.
Zagon IS; Wu Y; McLaughlin PJ
J Invest Dermatol; 1996 Mar; 106(3):490-7. PubMed ID: 8648182
[TBL] [Abstract][Full Text] [Related]
23. Gene-peptide relationships in the developing rat brain: the response of preproenkephalin mRNA and [Met5]-enkephalin to acute opioid antagonist (naltrexone) exposure.
Zagon IS; McLaughlin PJ
Brain Res Mol Brain Res; 1995 Oct; 33(1):111-20. PubMed ID: 8774952
[TBL] [Abstract][Full Text] [Related]
24. Opioid growth factor inhibits intimal hyperplasia in balloon-injured rat carotid artery.
Zagon IS; Essis FM; Verderame MF; Healy DA; Atnip RG; McLaughlin PJ
J Vasc Surg; 2003 Mar; 37(3):636-43. PubMed ID: 12618704
[TBL] [Abstract][Full Text] [Related]
25. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
[TBL] [Abstract][Full Text] [Related]
26. The expression and function of the OGF-OGFr axis - a tonically active negative regulator of growth - in COS cells.
Zagon IS; Verderame MF; McLaughlin PJ
Neuropeptides; 2003 Oct; 37(5):290-7. PubMed ID: 14607106
[TBL] [Abstract][Full Text] [Related]
27. Homeostasis of ocular surface epithelium in the rat is regulated by opioid growth factor.
Zagon IS; Sassani JW; Kane ER; McLaughlin PJ
Brain Res; 1997 Jun; 759(1):92-102. PubMed ID: 9219867
[TBL] [Abstract][Full Text] [Related]
28. Opioids and the apoptotic pathway in human cancer cells.
Zagon IS; McLaughlin PJ
Neuropeptides; 2003 Apr; 37(2):79-88. PubMed ID: 12747939
[TBL] [Abstract][Full Text] [Related]
29. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
McLaughlin PJ; Zagon IS
Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
[TBL] [Abstract][Full Text] [Related]
30. Reduction of alcohol drinking and upregulation of opioid receptors by oral naltrexone in AA rats.
Parkes H; Sinclair JD
Alcohol; 2000 Jul; 21(3):215-21. PubMed ID: 11091024
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone.
Hytrek SD; McLaughlin PJ; Lang CM; Zagon IS
Cancer Lett; 1996 Mar; 101(2):159-64. PubMed ID: 8620464
[TBL] [Abstract][Full Text] [Related]
32. Topical treatment with the opioid antagonist naltrexone facilitates closure of full-thickness wounds in diabetic rats.
McLaughlin PJ; Pothering CA; Immonen JA; Zagon IS
Exp Biol Med (Maywood); 2011 Oct; 236(10):1122-32. PubMed ID: 21917593
[TBL] [Abstract][Full Text] [Related]
33. Chronic opioid antagonist treatment selectively regulates trafficking and signaling proteins in mouse spinal cord.
Patel CN; Rajashekara V; Patel K; Purohit V; Yoburn BC
Synapse; 2003 Oct; 50(1):67-76. PubMed ID: 12872295
[TBL] [Abstract][Full Text] [Related]
34. The effect of nimodipine on opioid antagonist-induced upregulation and supersensitivity.
Lee SC; Yoburn BC
Pharmacol Biochem Behav; 2000 Jun; 66(2):347-51. PubMed ID: 10880689
[TBL] [Abstract][Full Text] [Related]
35. Ex vivo studies for the passive transdermal delivery of low-dose naltrexone from a cream; detection of naltrexone and its active metabolite, 6β-naltrexol, using a novel LC Q-ToF MS assay.
Dodou K; Armstrong A; Kelly I; Wilkinson S; Carr K; Shattock P; Whiteley P
Pharm Dev Technol; 2015; 20(6):694-701. PubMed ID: 24785567
[TBL] [Abstract][Full Text] [Related]
36. Detection of opioid receptors on murine lymphocytes by indirect immunofluorescence: mature normal and tumor bearing mice lymphocytes.
Karaji AG; Khansari N; Ansary B; Dehpour Ar
Int Immunopharmacol; 2005 Jun; 5(6):1019-27. PubMed ID: 15829417
[TBL] [Abstract][Full Text] [Related]
37. Adaptation of homeostatic ocular surface epithelium to chronic treatment with the opioid antagonist naltrexone.
Zagon IS; Sassani JW; McLaughlin PJ
Cornea; 2006 Aug; 25(7):821-9. PubMed ID: 17068460
[TBL] [Abstract][Full Text] [Related]
38. Naltrexone effects on male sexual behavior, corticosterone, and testosterone in stressed male rats.
Retana-Márquez S; Bonilla-Jaime H; Vázquez-Palacios G; Martínez-García R
Physiol Behav; 2009 Feb; 96(2):333-42. PubMed ID: 19027764
[TBL] [Abstract][Full Text] [Related]
39. Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck.
McLaughlin PJ; Stucki JK; Zagon IS
Head Neck; 2012 Apr; 34(4):513-9. PubMed ID: 21584896
[TBL] [Abstract][Full Text] [Related]
40. Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer.
Zagon IS; Porterfield NK; McLaughlin PJ
Exp Biol Med (Maywood); 2013 Jun; 238(6):589-99. PubMed ID: 23918871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
